PTC Therapeutics

Aug 08, 2024

•

Mar 31, 2024

PTC Therapeutics Q2 2024 Earnings Report

Previous year: -$1.48

Previous year: $88.4M

-21.4%

Non-GAAP R&D Expenses

Previous year: -$20.4M

-400.4%

Total Assets

$1.79B

Previous year: $1.34B

+33.7%

PTC Therapeutics

Unlock previous datapoints

Upgrade

PTC Therapeutics

Unlock previous datapoints

Upgrade

Revenue by Segment

Translarna Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Emflaza Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Evrysdi Royalty Revenue

CapyFin.com

Net Product Revenue

CapyFin.com

Royalty Revenue

CapyFin.com

Manufacturing Revenue

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View PTC Therapeutics

Products

Get in Touch

Resources

PTC Therapeutics

PTC Therapeutics Q2 2024 Earnings Report

PTC Therapeutics

PTC Therapeutics

Revenue by Segment

Translarna Revenue

Emflaza Revenue

Evrysdi Royalty Revenue

Net Product Revenue

Royalty Revenue

Manufacturing Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings

Company Overview

PTC Therapeutics Revenue by Segment